Eohilia denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for eohilia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Step Therapy Before Approving Eohilia

Step therapy — sometimes called "fail first" — is Aetna's policy of requiring patients to try and document inadequate response to one or more lower-cost or preferred treatments before the plan will cover a specialty medication like Eohilia (budesonide oral suspension) for eosinophilic esophagitis (EoE). Aetna's step-therapy protocol for EoE typically requires evidence that certain dietary, pharmacological, or other management approaches were tried and did not achieve adequate clinical control before Eohilia will be authorized.

Step-therapy denials are frequently overturned on appeal when prior-treatment history is thoroughly documented — or when a clinical exception applies because the required step-therapy agent is contraindicated, not appropriate for the patient's specific situation, or was already tried before the current insurance coverage began.

## Your Federal Appeal Rights

• Step-therapy exception and internal appeal: Most states have enacted step-therapy exception laws requiring insurers to grant an exception when prior trials are documented, the step-therapy agent is contraindicated, or step-therapy would delay medically necessary treatment. Even without a state law, ACA §2719 and ERISA §503 require a full-and-fair review.
• External review (ACA §2719): After exhausting internal appeals, you may request binding independent external review. The IRO will evaluate whether requiring additional step-therapy steps is consistent with generally accepted standards of care for EoE.
• Expedited pathway: When waiting for standard review would seriously jeopardize your health, request expedited review — internal plans must respond within 72 hours; external IROs within 72 hours as well.
• Four-month window: External review requests are generally due within approximately four months of the final internal denial.

## The Concrete Appeal Process

1. Request the complete step-therapy criteria Aetna requires for Eohilia and the list of required step agents. 2. Identify which steps have already been completed, and gather documentation proving each one. 3. If a required step has not been tried, work with your prescriber to document why it is clinically inappropriate for this patient. 4. Submit a written internal appeal — or a step-therapy exception request — with the full documentation package. 5. If denied, proceed to external review.

## Documentation to Gather

• Prior EoE treatment history: Dated records for every therapy already tried — dietary elimination protocols, proton-pump inhibitor trials, any other EoE-directed therapies — including start and end dates, doses used, and documented clinical outcomes or reasons for discontinuation.
• Reasons step-therapy agents are inappropriate: If any required step agent has not been tried, prescriber notes explaining the specific clinical reason it would be inappropriate or contraindicated for this patient.
• Current EoE severity: Recent endoscopy and biopsy results, symptom-severity documentation, and any validated outcome measures from office visits.
• Prescriber step-therapy exception letter: A detailed letter from the treating gastroenterologist or allergist explaining why Eohilia is medically necessary now, addressing each required step and why the step-therapy protocol should be waived or deemed satisfied.

## Criteria-Mapping Strategy

Build a treatment-history timeline: list each step-therapy agent in Aetna's protocol in one column; in the adjacent column, cite the chart date, clinical outcome, and reason the step is complete or should be excepted. Pair this table with a prescriber letter that explicitly invokes applicable professional society guidance for EoE management (reference the organization, not specific thresholds). This structured format forces the reviewer to engage with each step individually rather than issuing a blanket denial.